ClinicalTrials.gg

Program

HRS-7085

A development code. Also written as “HRS-7085 tablets” and “HRS-7085 Tablets”.

In Jiangsu HengRui Medicine's pipeline, miR 124. Its studies are mostly in Colitis, Ulcerative · Inflammatory Bowel Diseases, led by Jiangsu HengRui Medicine.

Furthest: phase 2, since Sep 29, 20254 company-led studies, 3 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine43 open or runningphase 2since Sep 29, 2025Nov 27, 2022Dec 2026phase 2 · NCT07229950
  • Named in Jiangsu HengRui Medicine’s own pipeline as HRS-7085, phase 2, as of Jul 31, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 27, 2022First study: phase 1 study in Inflammatory Bowel DiseasesFirst studyNCT05638347 · 16 enrolled · Australia
  2. Dec 10, 2023Phase 1 study in Inflammatory Bowel DiseasesNCT06175949 · 70 planned
  3. Sep 29, 2025Phase 2 study in Adult Patients With Moderately to Severely Active Ulcerative ColitisNCT07229950 · 48 planned · China
  4. Jul 31, 2026Phase 1 study in Moderate to Severe Ulcerative ColitisNCT07760831 · 8 planned · Moldova

Ahead

  1. Dec 2026Primary completion: phase 2 study in Adult Patients With Moderately to Severely Active Ulcerative ColitisNCT07229950
  2. Apr 2027Primary completion: phase 1 study in Moderate to Severe Ulcerative ColitisNCT07760831

TargetBeta

“miR 124”the company's pipeline, read by Claude · source

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07760831Moderate to Severe Ulcerative Colitis · Moldova1Not yet recruitingApr 20278
NCT07229950Adult Patients With Moderately to Severely Active Ulcerative Colitis · China2RecruitingDec 202648
NCT06175949Inflammatory Bowel Diseases1Not yet recruitingJun 202470
NCT05638347Inflammatory Bowel Diseases · Australia1CompletedMar 16, 202316

How it is read

Names in the registry

  • “HRS-7085 tablets”, 2 entries
  • “HRS-7085”, 2 entries
  • “HRS-7085 Tablets”, 1 entry

Codes read as this program: HRS7085.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.